CVMP recommendations on limited market classification and eligibility for authorisation under Article 23
Timetable: Post-authorisation safety study (PASS) protocols and final results
Timetable: Initial (Full) marketing authorisation application - ATMP
Organisation chart: Advisory functions
Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
Herbal medicinal product: Hippocastani cortexArray, F: Assessment finalised
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024
EMA closed 9-10 May
Information session on Call for Proposals "EU 4 AMA: leveraging European expertise for medicines regulation in Africa", Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 May 2024, 10:00 (CEST) to 22 May 2024, 11:00 (CEST)
List of medicines currently in PRIME scheme